MedPath

Spontaneous Atrio Ventricular Conduction Preservation

Phase 4
Completed
Conditions
Sinus Node Dysfunction
Bradycardia-Tachycardia Syndrome
Paroxysmal Atrioventricular Block
Interventions
Device: Symphony D 2450
Device: Symphony DR 2550
Registration Number
NCT00655213
Lead Sponsor
LivaNova
Brief Summary

In case of sinus node dysfunction, it is often necessary to choose the safer option provided by a DDD pacemaker even though the most appropriate mode of pacing is AAI mode.

In addition to saving energy, the latter mode allows spontaneous ventricular activation, the haemodynamic consequences of which are, in most cases, better than those obtained with dual chamber pacing.

Recent studies as the MOST study suggest also that ventricular desynchronization imposed by right ventricular apical pacing even when AV synchrony is preserved increases the risk of atrial fibrillation in patients with SND. Similar results were already given by anterior studies (PIPAF) which, taking into account the percentage of ventricular pacing, suggested that AF prevention algorithm in combination with a preserved native conduction are efficient in reducing AF burden.

However, current practice is to implant a dual chamber pacemaker to prevent the risk of atrioventricular block (AVB) even if DDDR pacing with a fixed long AV delay was found inefficient in reducing ventricular pacing and was associated with a high risk of arrhythmias.

The Symphony 2550 cardiac pacemaker offers pacing modes that automatically switch from AAI(R) mode to DDD(R) or DDI(R) in event of severe atrioventricular conduction disorder, irrespective of whether or not these are accompanied by an atrial arrhythmia, returning spontaneously to AAI(R) mode as soon as the spontaneous AV conduction has resumed. These 2 particular modes are called the AAI SafeR and DDD/AMC (R) mode.

The main differences between both modes are that (i) AAI SafeR does not trigger any AV Delay after a sensed or paced atrial event which allows long PR intervals or even limited ventricular pauses with no switch to DDD(R), while (ii) DDD/AMC (R) is able to optimize AV Delay after switching to DDD(R) according to measured spontaneous conduction times and to provide an acceleration in case of vaso-vagal syndrome. This pacing mode has previously been assessed in clinical studies.

This study intends to demonstrate that the automatic modes switching significantly reduce the percentage of ventricular pacing in patients implanted with a spontaneous AV conduction and reduce the occurrence of atrial arrhythmias, on a mid-term follow-up period, in comparison to standard DDD pacing with long AVDelay.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
622
Inclusion Criteria
  • Patient has been primo-implanted with a Symphony™ 2550 or 2450 devices for less than 3 months
  • Patient with a normal spontaneous AV conduction at rest (PR < 250 ms)
  • Patient implanted for Sinus Node Dysfunction, Braycardia-Tachycardia Syndrome, carotid sinus syndrome/ vaso vagal syndrome or paroxistic AV Block
  • Patient implanted with a bipolar right-atrial lead and ventricular lead available in the local market
  • Patient has signed a consent form after having received the appropriate information
Exclusion Criteria
  • Permanent 1st, 2nd or 3rd AV block
  • Patient having a medical status complying with one of the following cases
  • patient suffering from sustained ventricular arrhythmias
  • patient having sustained a myocardial infarction within the last month
  • patient having undergone cardiac surgery within the last month
  • patient suffering from severe aortic stenosis
  • patient suffering from unstable angina pectoris
  • patient presents with permanent atrial arrhythmias
  • Patient is not able to understand the study objectives and protocol or refuses to co-operate
  • Patient is not available for scheduled follow-up
  • Patient has a life expectancy less than one year
  • Patient is included into another clinical study
  • Patient is minor or a pregnant woman

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
3Symphony D 2450DDDAMC mode programming
1Symphony D 2450AAISafeR mode programming
1Symphony DR 2550AAISafeR mode programming
2Symphony D 2450DDD with long AV Delay programming
2Symphony DR 2550DDD with long AV Delay programming
3Symphony DR 2550DDDAMC mode programming
4Symphony D 2450AAISafer mode programming in non randomized patients
4Symphony DR 2550AAISafer mode programming in non randomized patients
Primary Outcome Measures
NameTimeMethod
mean percentage of ventricular pacing between the randomized branches on a two-months period (M3 visit)2 months
mean percentage of ventricular pacing between the studied groups during the whole study (up to 1 year).12 months
Secondary Outcome Measures
NameTimeMethod
percentage of ventricular pacing two month after randomization versus the percentage reported at the end of the first month follow-up in AAIsafeR mode.12 months
AF burden relatively to the branch of the protocol12 months
evolution of conduction disturbances by documentings nature, number and duration of ario-ventricular blocks.12 months

Trial Locations

Locations (63)

CHU Hopital C. Nicolle

🇫🇷

Rouen, France

KH Holweide

🇩🇪

Koln, Germany

Onze lieve Vrouw ziekenhuis

🇧🇪

Aalst, Belgium

CH Albi

🇫🇷

Albi, France

St.Josef-Stift Bremen

🇩🇪

Bremen, Germany

CHU d'Angers

🇫🇷

Angers, France

Nouvelles Cliniques Nantaises

🇫🇷

Nantes, France

Hôpital universitaire Brugmann

🇧🇪

Bruxelles, Belgium

Europa ziekenhuis

🇧🇪

Campus st. Elisabeth Uccle, Belgium

CH de CASTRES

🇫🇷

Castres-mazamet, France

Universitätskliniken Bonn

🇩🇪

Bonn, Germany

Herzzentrum Kassel

🇩🇪

Kassel, Germany

Univ. Marburg

🇩🇪

Marburg, Germany

St. Salvator Krankenhaus Halberstadt

🇩🇪

Halberstadt, Germany

Barts and The London NHS Trust

🇬🇧

London, United Kingdom

Ospedale Umberto I

🇮🇹

Mestre (VE), Italy

Bristol Royal Infirmary

🇬🇧

Bristol, United Kingdom

Klinikum Lüdenscheid

🇩🇪

Luedenscheid, Germany

Hürth Sana

🇩🇪

Hürth, Germany

Rot-Kreuz Krankenhaus

🇩🇪

Munchen, Germany

Praxis Bitar

🇩🇪

Peine, Germany

Prof. Frey Praxis Starnberg

🇩🇪

Starnberg, Germany

Klinikum Wolgast

🇩🇪

Wolgast, Germany

Ospedale Moscati

🇮🇹

Avellino, Italy

Univ. Mainz

🇩🇪

Mainz, Germany

Klinikum Bogenhausen

🇩🇪

Munchen, Germany

Uni Ulm

🇩🇪

Ulm, Germany

Städt. Kh. Lüneburg

🇩🇪

Lüneburg, Germany

Klinkum Memmingen

🇩🇪

Memmingen, Germany

St Thomas' Hospital,

🇬🇧

London, United Kingdom

Ospedale Civili Reuniti

🇮🇹

Venezia, Italy

Ospedale S. G. Battista

🇮🇹

Foligno (PG), Italy

Queens Hospital

🇬🇧

Burton on Trent, United Kingdom

Centre Hospitalier

🇫🇷

Aix-en-Provence, France

CHU Jean Minjoz

🇫🇷

Besancon, France

Hospice St-Jacques-Hôspital G.Montpied

🇫🇷

Clermont-Ferrand, France

CHRU de Lille - Hôpital Cardiologique

🇫🇷

Lille, France

CHU de Limoges

🇫🇷

Limoges, France

CH Montpellier

🇫🇷

Montpellier, France

CH Emile Muller

🇫🇷

Mulhouse, France

CHU de Nantes

🇫🇷

Nantes, France

CHU de Nice

🇫🇷

Nice, France

CHU Pontchaillou

🇫🇷

Rennes, France

InParys Cardiology

🇫🇷

St Cloud, France

CHU de Nancy

🇫🇷

Vandoeuvre les Nancy, France

Leeds General Infirmary

🇬🇧

Leeds, United Kingdom

Universitätsklinikum Schleswig-Holstein

🇩🇪

Lübeck, Germany

Uni Regensburg

🇩🇪

Regensburg, Germany

CHU - Hopital Michallon

🇫🇷

Grenoble, France

Marien Hospital

🇩🇪

Bonn, Germany

Clinique Bizet

🇫🇷

Paris cedex 16, France

Augustinum

🇩🇪

Munchen, Germany

Holzminden Praxis Bub

🇩🇪

Holzminden, Germany

Ospedale Civile

🇮🇹

Voghera, Italy

Ospedale Mellini

🇮🇹

Chiari (BS), Italy

Istituto Policlinico

🇮🇹

San Donato, Italy

Waren-Müritzklinikum

🇩🇪

Waren, Germany

Queen Elizabeth Hospital

🇬🇧

Birmingham, United Kingdom

CHU - Tivoli

🇧🇪

Tivoli, Belgium

Hôpital Vésale (univ.)

🇧🇪

Montigny Le Tilleul, Belgium

Clinique Louis Caty

🇧🇪

Baudour, Belgium

Heiling Hart van Jezus

🇧🇪

Moen, Belgium

Castle Hill Hospital

🇬🇧

Hull, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath